Pu Yan

TL;DR: In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value, but BRAF is prognostic for OS in MS-L/S tumors.

TL;DR: Colorectal carcinoma side is associated with differences in key molecular features, some immediately druggable, with important prognostic effects which are maintained in metastatic lesions, and stratification of patients by side for retrospective and prospective analyses of drug efficacy and prognosis is justified.

TL;DR: The proposed subtypes provide a novel perspective on the heterogeneity of CRC and should be further explored retrospectively on existing clinical trial datasets and, when sufficiently robust, be prospectively assessed for clinical relevance in terms of prognosis and treatment response predictive capacity.

TL;DR: This is the first gene in which methylation of its promoter sequence has been found to be positively correlated with gene expression and the results suggest that methylation may be involved in the regulation of hTERT gene expression.

TL;DR: Interestingly, T3N1 tumors with MSI-high status and retained SMAD4 expression had outcomes similar to stage II disease, suggesting including molecular markers with independent prognostic value might allow more accurate prediction of prognosis than TNM staging alone.